

Sugiyama 10 527 692 = SEQ ID NO: 2 = CMTWNQMNL

Friday March 23, 2007

LOGINID:SSPTAHPY1654

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:15:37 ON 23 MAR 2007

=> file registry

FILE 'REGISTRY' ENTERED AT 15:16:04 ON 23 MAR 2007

=> s CMTWNQMNL/sqsp
L1 275 CMTWNQMNL/SQSP

=> file CAPLUS

FILE 'CAPLUS' ENTERED AT 15:17:24 ON 23 MAR 2007

=> s L1 and PATENT/dt
71 L1
5645792 PATENT/DT
L2 46 L1 AND PATENT/DT

=> s L2 and pd<2004
23853187 PD<2004
(PD<20040000)
L3 27 L2 AND PD<2004

=> s L2 and pd<2003
22822726 PD<2003
(PD<20030000)
L4 20 L2 AND PD<2003

=> s L2 and pd<2002
21852382 PD<2002
(PD<20020000)
L5 9 L2 AND PD<2002

=> d L5 1-9 bib abs

L5 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:636212 CAPLUS
DN 135:205529
TI Wilms' tumor antigen peptide compositions and methods for diagnosis and
therapy of malignant mesothelioma
IN Cheever, Martin A.; Gaiger, Alexander
PA Corixa Corporation, USA
SO PCT Int. Appl., 243 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001062920	A2	20010830	WO 2001-US5702	20010222 <--
	WO 2001062920	A3	20020718		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

CA 2401070	A1	20010830	CA 2001-2401070.	20010222 <--
EP 1261711	A2	20021204	EP 2001-920134	20010222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003082194	A1	20030501	US 2001-791477	20010222
JP 2003524021	T	20030812	JP 2001-562694	20010222
NZ 521430	A	20040430	NZ 2001-521430	20010222
PRAI US 2000-184070P	P	20000222		
WO 2001-US5702	W	20010222		

AB Disclosed are compns. and methods for the diagnosis and therapy of Wilms' tumor antigen-assocd. cancers, and in particular, mesotheliomas. The invention is based upon the discovery that immune and T cell responses to particular antigenic peptide fragments of the Wilms' tumor (WT) gene product (e.g., WT1) can provide particularly advantageous compns. and methods for the diagnosis, prophylaxis and/or therapy for an animal having, suspected of having, or at risk for developing one or more malignant diseases characterized by increased WT1 gene expression, and in particular, malignant pleural mesothelioma in a human. Human and murine WT1-derived peptides induce TH and antibody responses in immunized mice, and bind to a variety of human HLA, mouse MHC class I, and cattle, HLA antigens. In particular embodiments, the invention provides new, effective methods, compns. and kits for eliciting immune and T cell response to Wilms' tumor antigen polypeptide-derived antigenic fragments, and methods for the use of such compns. for diagnosis, detection, treatment, monitoring, and/or prevention of human malignant pleural mesothelioma.

L5 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:265565 CAPLUS

DN 134:291103

TI Methods of using a Mycobacterium tuberculosis coding sequence in gene and protein fusions to facilitate stable and high yield expression of heterologous proteins

IN Skeiky, Yasir; Guderian, Jeffrey

PA Corixa Corporation, USA

SO PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001025401	A2	20010412	WO 2000-US27652	20001006 <--
	WO 2001025401	A9	20020926		
	WO 2001025401	A3	20050203		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2386854	A1	20010412	CA 2000-2386854	20001006 <--
	AU 200079972	A	20010510	AU 2000-79972	20001006 <--
	AU 779846	B2	20050217		
	JP 2003527830	T	20030924	JP 2001-528556	20001006
	EP 1517913	A2	20050330	EP 2000-970619	20001006
	EP 1517913	B1	20070221		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	US 7009042	B1	20060307	US 2000-684215	20001006
	US 2006040356	A1	20060223	US 2005-222451	20050907
PRAI	US 1999-158585P	P	19991007		
	US 2000-684215	A3	20001006		
	WO 2000-US27652	W	20001006		

AB The present invention relates generally to nucleic acid and amino acid sequences of a fusion polypeptide comprising a Mycobacterium tuberculosis polypeptide, and a heterologous polypeptide of interest, expression vectors and host cells comprising such nucleic acids, and methods for

producing such fusion polypeptides. In particular, the invention relates to materials and methods of using such M. tuberculosis sequence as a fusion partner to facilitate the stable and high yield expression of recombinant heterologous polypeptides of both eukaryotic and prokaryotic origin. A 14 kD C-terminal fragment (referred to as Ral2) of the Mycobacterium tuberculosis serine protease MTB32A can be expressed as a sol. protein. Use of the Ral2 sequences as a fusion partner is illustrated with construction of expression vectors, expression in Escherichia coli, and protein purifn. of a (His-tag) Ral2-DPPD fusion protein. Antiserum raised against the Ral2-DPPD fusion protein recognized the DPPD protein in immunoblotting anal. Ral2-WT1, Ral2-mammaglobin, and Ral2-H9-32A fusion proteins were also constructed and shorter or longer Ral2 sequences were fused with full length human mammaglobin gene sequences.

L5 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:265455 CAPLUS

DN 134:309686

TI Compositions and methods for WT1 specific immunotherapy

IN Skeiky, Yasir A. W.; Xu, Jiangchun; Cheever, Martin A.; Reed, Steven G.

PA Corixa Corporation, USA

SO PCT Int. Appl., 228 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001025273	A2	20010412	WO 2000-US27465	20001004 <--
	WO 2001025273	A3	20020711		
	WO 2001025273	A9	20030130		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI US 1999-157459P P 19991004

AB Compns. and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compns. comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compns. may be used, for example, for the prevention and treatment of metastatic diseases.

L5 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2000:314730 CAPLUS

DN 132:333396

TI Immunotherapy of cancer using epitopes of WT-1 and GATA-1 transcription factors

IN Stauss, Hans Josef; Gao, Liqun

PA Imperial College Innovations Limited, UK

SO PCT Int. Appl., 93 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000026249	A1	20000511	WO 1999-GB3572	19991102 <--
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,			

CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2348956	A1	20000511	CA 1999-2348956	19991102 <--
AU 9964797	A1	20000522	AU 1999-64797	19991102 <--
AU 770752	B2	20040304		
EP 1127068	A1	20010829	EP 1999-952682	19991102 <--
EP 1127068	B1	20060118		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
NZ 511454	A	20040130	NZ 1999-511454	19991102
EP 1619202	A2	20060125	EP 2005-23645	19991102
EP 1619202	A3	20060308		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
AT 316099	T	20060215	AT 1999-952682	19991102
ES 2252982	T3	20060516	ES 1999-952682	19991102
ZA 2001003943	A	20030815	ZA 2001-3943	20010515
PRAI GB 1998-23897	A	19981102		
EP 1999-952682	A3	19991102		
WO 1999-GB3572	W	19991102		

AB The authors disclose that the peptides RMFPNAPYL or CMTWNQMNL are epitopes for cytotoxic T-cells recognizing WT-1 in an HLA-A2-restricted manner. In addn. the peptide is HLMPPFGPLL is a CTL epitope of human GATA-1 transcription factor. The peptides, and polynucleotides encoding them, may be useful as cancer vaccines.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:227680 CAPLUS
DN 132:264096
TI Compositions and methods for WT1 specific immunotherapy
IN Gaiger, Alexander; Cheever, Martin
PA Corixa Corporation, USA
SO PCT Int. Appl., 193 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 12

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000018795	A2	20000406	WO 1999-US22819	19990930 <--
	WO 2000018795	A3	20001026		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 7063854	B1	20060620	US 1998-164223	19980930
	CA 2349442	A1	20000406	CA 1999-2349442	19990930 <--
	AU 9964078	A	20000417	AU 1999-64078	19990930 <--
	EP 1117687	A2	20010725	EP 1999-951690	19990930 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9914116	A	20020115	BR 1999-14116	19990930
	TR 200101482	T2	20020121	TR 2001-200101482	19990930
	HU 200103598	A2	20020128	HU 2001-3598	19990930
	JP 2002525099	T	20020813	JP 2000-572253	19990930
	NZ 510600	A	20031219	NZ 1999-510600	19990930
	RU 2237674	C2	20041010	RU 2001-111834	19990930
	NO 2001001613	A	20010529	NO 2001-1613	20010329 <--
	ZA 2001002606	A	20020930	ZA 2001-2606	20010329
	AU 2003257511	A1	20031120	AU 2003-257511	20031023
	US 2006121046	A1	20060608	US 2006-340431	20060125
	JP 2007001984	A	20070111	JP 2006-227215	20060823
PRAI	US 1998-164223	A	19980930		
	US 1999-276484	A	19990325		
	AU 1999-64078	A3	19990930		
	JP 2000-572253	A3	19990930		

WO 1999-US22819 W 19990930

AB Compns. and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compns. comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compns. may be used, for example, for the prevention and treatment of metastatic diseases. Such compn. may also be used for monitoring the effectiveness of immunization and therapy by detg. activation of T cell proliferation or cytolytic activity.

L5 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2000:98605 CAPLUS
 DN 132:150601
 TI Cancer antigens based on tumor suppressor gene WT1 product
 IN Sugiyama, Haruo; Oka, Yoshihiro
 PA Japan
 SO PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000006602	A1	20000210	WO 1999-JP4130	19990730 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2337743	A1	20000210	CA 1999-2337743	19990730 <--
AU 9949321	A1	20000221	AU 1999-49321	19990730 <--
BR 9912663	A	20010502	BR 1999-12663	19990730 <--
EP 1103564	A1	20010530	EP 1999-933205	19990730 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1560078	A	20050105	CN 2004-10049270	19990730
CN 1762490	A	20060426	CN 2005-10099511	19990730
US 7030212	B1	20060418	US 2001-744815	20010130
HK 1038929	A1	20050506	HK 2002-100403	20020118
US 2005266014	A1	20051201	US 2005-196459	20050804
US 2006093615	A1	20060504	US 2006-322245	20060103
PRAI JP 1998-218093	A	19980731		
CN 1999-810209	A3	19990730		
CN 2004-10049270	A3	19990730		
WO 1999-JP4130	W	19990730		
US 2001-744815	A3	20010130		

AB Provided is a cancer antigen, i.e. Wilms' tumor suppressor gene WT1 product, or a peptide consisting of 7 to 30 consecutive amino acids in the amino acid sequence encoded by the above gene which contains an anchor amino acid that binds to major histocompatibility complex (MHC) class I. The cancer antigen or peptides are useful as cancer vaccines.

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1998:180573 CAPLUS
 DN 128:214200
 TI Localization and characterization of the Wilm's tumor gene
 IN Call, Katherine M.; Glaser, Thomas M.; Ito, Caryn Y.; Buckler, Alan J.; Pelletier, Jerry; Haber, Daniel A.; Rose, Elise A.; Housman, David E.; Bruening, Wendy; Darveau, Andre
 PA Massachusetts Institute of Technology, USA
 SO U.S., 42 pp., Cont.-in-part of U.S. Ser. No. 614,161, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5726288	A	19980310	US 1993-102942	19930802 <--
	US 6316599	B1	20011113	US 1998-37179	19980309 <--
	US 2002082394	A1	20020627	US 2001-929315	20010814
	US 6943011	B2	20050913		
	US 2002128196	A1	20020912	US 2001-993215	20011112
PRAI	US 1989-435780	B2	19891113		
	US 1990-614161	B2	19901113		
	US 1993-102942	A3	19930802		
	US 1998-37179	A3	19980309		
AB	The Wilms' tumor gene assocd. with 11p3 locus on the human chromosome, as well as a method of analyzing cells for the gene, is described and characterized. The gene encodes a transcription unit .apprx.50 kb in size and a mRNA of .apprx.3 kb, which is expressed in predominantly in kidney and gonadal tissue. The gene is alternative spliced producing 4 very similar mRNA transcripts. The polypeptides encoded by the Wilms' tumor DNA includes 4 "zinc fingers" and a region rich in proline and glutamine, suggesting that the polypeptide has a role in transcription regulation.				
RE.CNT	41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L5 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1996:42933 CAPLUS
DN 124:84903
TI Monoclonal antibodies to Wilm's tumor antigen and uses
IN Herlyn, Meenhard; Morris, Jennifer; Rauscher, Frank J., III; Rodeck, Ulrich
PA Wistar Institute of Anatomy and Biology, USA
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9529995	A1	19951109	WO 1995-US5523	19950425 <--
	W: AU, CA RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5622835	A	19970422	US 1994-234783	19940428 <--
	CA 2188663	A1	19951109	CA 1995-2188663	19950425 <--
	AU 9524679	A	19951129	AU 1995-24679	19950425 <--
	AU 699968	B2	19981217		
	EP 759071	A1	19970226	EP 1995-918949	19950425 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
PRAI	US 1994-234783	A	19940428		
	WO 1995-US5523	W	19950425		
AB	The present invention provides three unique monoclonal antibodies directed against a portion of the Wilms' tumor antigen. The monoclonal antibodies are used for detecting, monitoring and diagnosing malignancies characterized by over-expression or inappropriate expression of the WT1 protein. Also claimed are humanized, chimeric and bispecific antibodies, and method using the antibodies for detg. WT1 protein in blood, serum, plasma, synovial fluid, tissue, urine, bone marrow of patients with mesothelioma, prostate cancer, ovarian cancer, and leukemia. In example, clone pet11d-6F-derived recombinant WT1-6F antigen was prepd. for raising monoclonal antibodies for immunoassay.				

L5 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1991:529116 CAPLUS
DN 115:129116
TI Localization and characterization of the Wilm's tumor gene
IN Call, Katherine M.; Glaser, Thomas M.; Ito, Caryn Y.; Buckler, Alan J.; Pelletier, Jerry; Haber, Daniel A.; Rose, Elise A.; Housman, David E.
PA Massachusetts Institute of Technology, USA
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

PI	WO 9107509	A1	19910530	WO 1990-US6629	19901113 <--
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	EP 453560	A1	19911030	EP 1991-901084	19901113 <--
	EP 453560	B1	19990526		
	R: CH, DE, FR, GB, IT, LI				
	JP 04503014	T	19920604	JP 1991-501474	19901113 <--
	JP 3393867	B2	20030407		
	US 5350840	A	19940927	US 1991-795323	19911120 <--
PRAI	US 1989-435780	A	19891113		
	WO 1990-US6629	W	19901113		
AB	<p>A gene mapping to human chromosome 11q13 assocd. with Wilms' tumor is cloned and characterized. The gene and corresponding cDNA are useful for study of the etiol. (no data) and diagnosis of the disease. Somatic cell hybridization was used to prep. cell lines contg. the short arm of human chromosome 11. A cosmid bank prepd. from this was screened for human sequences and 11p13 sequences confirmed by somatic cell mapping. Subsequently a cDNA corresponding to one of these clones was isolated. Anal. of the cDNA sequence showed possible zinc fingers in the protein and possible alternative splicing patterns for the primary transcript. The protein was manufd. as an insol. fusion protein with glutathione-S-transferase by expression of a chimeric gene in Escherichia coli.</p>				

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 15:27:31 ON 23 MAR 2007